Argos Therapeutics Inc. (NASDAQ:ARGS) Given Average Rating of “Buy” by Brokerages
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) have been assigned an average recommendation of “Buy” from the eight ratings firms that are presently covering the stock. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $11.50.
A number of brokerages have weighed in on ARGS. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Monday, August 15th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a report on Friday, June 17th. FBR & Co decreased their price objective on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 11th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a report on Monday, June 20th.
Argos Therapeutics (NASDAQ:ARGS) traded up 3.18% on Monday, hitting $4.87. 53,301 shares of the stock were exchanged. The firm’s market cap is $200.62 million. The stock’s 50 day moving average price is $4.85 and its 200 day moving average price is $5.92. Argos Therapeutics has a 52-week low of $1.61 and a 52-week high of $13.97.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/argos-therapeutics-inc-nasdaqargs-given-average-rating-of-buy-by-brokerages.html
Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Equities research analysts forecast that Argos Therapeutics will post ($1.56) earnings per share for the current year.
In related news, major shareholder International S. Pharmstandard purchased 43,618 shares of Argos Therapeutics stock in a transaction dated Thursday, September 29th. The shares were acquired at an average price of $4.56 per share, for a total transaction of $198,898.08. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder International S. Pharmstandard purchased 75,474 shares of Argos Therapeutics stock in a transaction dated Monday, August 22nd. The shares were bought at an average price of $4.24 per share, for a total transaction of $320,009.76. The disclosure for this purchase can be found here. Insiders own 61.64% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ARGS. BlackRock Fund Advisors raised its position in Argos Therapeutics by 880.1% in the second quarter. BlackRock Fund Advisors now owns 281,679 shares of the biopharmaceutical company’s stock valued at $1,727,000 after buying an additional 252,940 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock worth $2,314,000 after buying an additional 137,390 shares during the last quarter. State Street Corp acquired a new stake in shares of Argos Therapeutics during the second quarter worth about $741,000. BlackRock Institutional Trust Company N.A. acquired a new stake in shares of Argos Therapeutics during the second quarter worth about $363,000. Finally, Oxford Asset Management acquired a new stake in shares of Argos Therapeutics during the second quarter worth about $353,000. Institutional investors and hedge funds own 11.05% of the company’s stock.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.